Recital 233, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

Fifth, the Commission assessed the capacity of strain banks and investigated

whether the combination of the Parties’ strain banks would be unmatched by rivals and would raise a barrier to innovation. While Novozymes’ existing bank has c. [a number] physical strains and Chr. Hansen’s [a number] deposits (which Chr.

Hansen estimates would equate to c.[a number] strains), the Parties’ strain banks are largely differentiated in composition. Novozymes’ bank is focused on [information on strain banks] while Chr. Hansen’s is focused on [information on strain banks] given its dairy heritage.341 The results of the market investigation revealed that other competitors will have comparable strain banks and strain engineering capabilities; and the Parties can and do innovate based on publicly available genomes and strain banks.342 The Commission did not find any indications that a combination of the two complementary strain banks would create a competitive advantage that would negatively impact the overall innovation competition on the market. Moreover, publicly available sequences vastly outweigh the Parties’ sequences.